A Pharmaceutical Executive on Trump’s Tariff Strategy

Earlier this month, President Donald Trump announced the U.S. would impose up to a 200% tariff on imported pharmaceuticals, though he would give them up to a year and a half before fully implementing the tariffs. Trump’s goal is to bring more manufacturing to the United States, but one pharmaceutical CEO, Richard Saynor of Sandoz, says there is little incentive to build in the U.S. Jessica Mendoza hosts.

Further Listening:
- Why Trump Pushed His Tariff Deadline

- Inside the Surprise U.S.-China Trade Deal 

Sign up for WSJ’s free What’s News newsletter.

Learn more about your ad choices. Visit megaphone.fm/adchoices